Triple Negative Breast Cancer Clinical Trials

68 studies are recruiting for triple negative breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

   The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.

   Stage

   Phase 2

   Ages

   70 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07768436 on ClinicalTrials.gov

2. Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

   The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes i…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Run by

   Stanford University

   See if you can join NCT04768426 on ClinicalTrials.gov

3. Breast Cancer PSMA PET

   The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSM…

   Stage

   EARLY_Phase 1

   Ages

   18 to 90

   Site

   University of Iowa Healthcare, Iowa City, Iowa

   Run by

   Ahmad Shariftabrizi

   See if you can join NCT06586047 on ClinicalTrials.gov

4. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

   The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Uni of Alabama at Birmingham, Birmingham, Alabama

   Locations

   29 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06562192 on ClinicalTrials.gov

5. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

   This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists - Lake Nona, Orlando, Florida

   Locations

   10 in total

   Run by

   Compass Therapeutics

   See if you can join NCT06150664 on ClinicalTrials.gov

6. Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

   This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of North Carolina, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT06347068 on ClinicalTrials.gov

7. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

   The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

   Locations

   13 in total

   Run by

   Pfizer

   See if you can join NCT07318805 on ClinicalTrials.gov

8. Sacituzumab Govitecan In TNBC

   This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   5 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT04230109 on ClinicalTrials.gov

9. Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

   This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT07064018 on ClinicalTrials.gov

10. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

    Locations

    26 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

11. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center /ID# 276272, Duarte, California

    Locations

    48 in total

    Run by

    AbbVie

    See if you can join NCT05005403 on ClinicalTrials.gov

12. A Study of LY4175408 in Participants With Advanced Cancer

    The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stanford Medicine Cancer Center, Stanford, California

    Locations

    27 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07046923 on ClinicalTrials.gov

13. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at HealthONE, Denver, Colorado

    Locations

    15 in total

    Run by

    IDEAYA Biosciences

    See if you can join NCT07503808 on ClinicalTrials.gov

14. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

    This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    2 in total

    Run by

    Memgen, Inc.

    See if you can join NCT05076760 on ClinicalTrials.gov

15. ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

    This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are n…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Laura Huppert, MD, BA

    See if you can join NCT06224673 on ClinicalTrials.gov

16. A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

    This phase Ib trial tests the safety, side effects and best dose of anti-HLA-A2/NY-ESO-1 T-cell receptor (TCR)-transduced autologous T lymphocytes (A2-ESO-1 TCR-T cells) in treating patients with NY-ESO-1 overexpression positive triple negative breast cancer (TNBC) that has come back after a period…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC / Norris Comprehensive Cancer Center, Los Angeles, California

    Run by

    University of Southern California

    See if you can join NCT05989828 on ClinicalTrials.gov

17. NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

    This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardia…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Medical University of South Carolina, Charleston, South Carolina

    Run by

    Medical University of South Carolina

    See if you can join NCT06845319 on ClinicalTrials.gov

18. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacit…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California San Francisco, San Francisco, California

    Locations

    7 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04434040 on ClinicalTrials.gov

19. ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

    This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.

    Stage

    Not phased

    Ages

    18 and older

    Site

    UPMC Hillman Cancer, Pittsburgh, Pennsylvania

    Run by

    University of Pittsburgh

    See if you can join NCT07332975 on ClinicalTrials.gov

20. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stamford Hospital, Stamford, Connecticut

    Locations

    15 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04468061 on ClinicalTrials.gov

21. A Study of Tetrathiomolybdate (TM) Plus Capecitabine

    There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer. In the ph…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

    Locations

    3 in total

    Run by

    Dartmouth-Hitchcock Medical Center

    See if you can join NCT06134375 on ClinicalTrials.gov

22. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

    This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Zumutor Biologics Inc.

    See if you can join NCT06451497 on ClinicalTrials.gov

23. Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

    This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06435351 on ClinicalTrials.gov

24. Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

    To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06318897 on ClinicalTrials.gov

25. Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

    This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hartford Healthcare, Hartford, Connecticut

    Locations

    12 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT03808337 on ClinicalTrials.gov